
Amperity
Founded Year
2016Stage
Series D | AliveTotal Raised
$217.3MValuation
$0000Last Raised
$100M | 10 mos agoESPs containing Amperity
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Amperity's Products & Differentiation
See Amperity's products and how their products differentiate from alternatives and competitors
Datagrid
DataGrid is the multi-patented infrastructure that powers all the products in Amperity's Comprehensive Enterprise CDP.
Differentiation
+ connectors and integrations. We accept customer data in any format - we'll adapt to you.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Research containing Amperity
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Amperity in 4 CB Insights research briefs, most recently on Aug 11, 2021.


Expert Collections containing Amperity
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Amperity is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,112 items
Tech IPO Pipeline
568 items
ad tech
3,639 items
Artificial Intelligence
8,694 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Conference Exhibitors
5,302 items
Targeted Marketing Tech
432 items
This Collection includes companies building technology that enables marketing teams to identify, reach, and engage with consumers seamlessly across channels.
Amperity Patents
Amperity has filed 13 patents.
The 3 most popular patent topics include:
- Data management
- Database management systems
- Data modeling
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/8/2019 | 4/19/2022 | Database management systems, Data management, Relational database management systems, Statistical classification, Classification algorithms | Grant |
Application Date | 11/8/2019 |
---|---|
Grant Date | 4/19/2022 |
Title | |
Related Topics | Database management systems, Data management, Relational database management systems, Statistical classification, Classification algorithms |
Status | Grant |
Latest Amperity News
Apr 14, 2022
David Denton → The two major Covid-19 vaccine competitors, Pfizer and Moderna, will both have new finance chiefs within a week of each other: At Pfizer, David Denton will succeed 15-year vet Frank D’Amelio as CFO on May 2 after three years in charge of finances at home improvement chain Lowe’s. With Pfizer’s M&A wheels always spinning, Denton left as CFO of CVS Health shortly after playing an integral role in the acquisition of Aetna in late 2017. Meanwhile, David Meline is calling it quits at Moderna, heading back into retirement nearly two years into his tenure as CFO and yielding the stage to Jorge Gomez on May 9. Before taking the CFO job at dental products manufacturer Dentsply Sirona in 2019, Gomez was also finance chief during a 13-year run at Cardinal Health. Meline had retired as Amgen’s CFO until the Moderna position opened up. Michelle Werner → On the heels of Margo Georgiadis’ appointment , Flagship Pioneering has lined up two more CEO-partners , and Michelle Werner kicked things off as the new chief executive of tRNA-focused Alltrna. Since the summer of 2020, Werner was Novartis Oncology’s worldwide franchise head, solid tumors, and her Big Pharma credentials also extend to Bristol Myers Squibb and to AstraZeneca, where she rose to global franchise head in hematology. Shortly after she decamped for Novartis, Calquence won approval in the EU for adult patients with chronic lymphocytic leukemia, a year after the FDA gave it the go-ahead in the same indication. Michael Severino Then, the biotech incubator made a splash on Wednesday by enticing AbbVie president and vice chairman Michael Severino into a CEO-partner job for a company to be named later. Before his arrival at AbbVie in 2014, Severino closed out his 10 years at Amgen as SVP, global development and corporate CMO. Our Kyle LaHucik has more on each new CEO-partner. Nishan de Silva → The white-hot radiopharma space picked up another challenger in October 2021 with Radionetics Oncology, and the Crinetics spinout — backed by 5AM Ventures and Frazier Healthcare Partners — has found a CEO. Nishan de Silva, the president and COO at Poseida from 2015-18, had helmed AFYX Therapeutics and is currently a board member at Selecta Biosciences. He will also sit on the board at Radionetics while leading a team that is projected “to more than double over the coming year,” according to a release. Paulash Mohsen → Paulash Mohsen is getting his first opportunity as a CEO at Vesigen Therapeutics, a Harvard spinout whose platform tech is dubbed ARMMs (ARRDC1 Mediated Microvesicles). Mohsen spent the last seven years as CBO of Yumanity, a neuro biotech that’s hanging on for dear life after laying off 60% of the workforce. Yumanity’s pipeline fortunes have soured because of a partial clinical hold on its lead Parkinson’s candidate, and while the company explores its options to stay afloat, Mohsen has jumped ship to a company that launched in July 2020 with help from Leaps by Bayer and Morningside Ventures. → Mario David Saltarelli is stepping into atai Life Sciences platform company GABA Therapeutics as CEO and CMO, succeeding co-founder Ian Massey. Saltarelli takes over the helm — as the company is entering Phase II studies in anxiety, depression and other neurological indications for its lead compound — with a wealth of experience from exec roles at Neuron23 (CEO), Entrada Therapeutics (CMO), Sytimmune (CMO), Annexon Biosciences (CMO) and Mallinckrodt (CSO). This is all on top of other stints at Pfizer, Shire, Vertex, Alexion and Abbott. Ranna Parekh → The University of Texas MD Anderson Cancer Center will welcome Ranna Parekh as chief diversity, equity and inclusion officer on May 31. Parekh comes from the American College of Cardiology in Washington, where she was the organiza1tion’s first chief diversity and inclusion officer, and she’s also held DEI leadership posts at the American Psychiatric Association. Joerg Hornstein → Joerg Hornstein has bolted from AC Immune to become CFO and head of corporate functions for Lundbeck, which provided a foretaste of the industry-wide staff cuts we’re seeing today by slashing 300 jobs and shuttering its facility in India. Hornstein had handled finances at AC Immune since 2017 and also spent 12 years in multiple locations at Merck KGaA. As for Hornstein’s replacement at the Swiss neuro biotech, Chris Roberts will pinch-hit as interim CFO and has been promoted to VP, finance. Roberts joined Andrea Pfeifer’s crew as an associate VP in 2017 after more than a decade at Ernst & Young. AC Immune also made two other leadership moves with Howard Donovan as chief HR officer and the promotion of Julian Snow to VP, US finance & corporate development. Donovan pivots here from the World Economic Forum, where he was head of people and culture partners, people services and global reward. As with Roberts, Snow started at AC Immune five years ago, filling the role of associate VP, financial reporting. Gina Consylman → Gina Consylman has landed at Cyrus Mozayeni-led Vedere Bio II from bluebird bio as CFO. Consylman starts anew quickly at the ocular gene therapy player, which debuted in May 2021 with a $77 million Series A, after a dire quarterly filing coincided with her departure from bluebird bio. Consylman joined bluebird just eight months ago after seven years as CFO of Ironwood, which has had its own set of obstacles with its pipeline and saw CEO Mark Mallon leave for NeoGenomics last year. John Frank → DNA sequencing powerhouse Illumina has poached John Frank from Microsoft, naming him chief public affairs officer. Frank, whose first day will be April 18, wraps up a 28-year career with the tech giant, starting out as a senior attorney and ascending to deputy general counsel & chief of staff. Since March 2020, Frank has taken on the role of VP, United Nations affairs and international organizations. Sam Jackson → Sitting pretty with a $100 million financing round just a couple weeks ago and targeting LRRK2 and TYK2, CNS-focused Neuron23 has tapped Sam Jackson as CMO. Jackson hails from another neuro player, Alector, where he held the same position and where former Passage Bio exec Gary Romano will soon replace him. Jackson is a Genentech and Amgen vet who was also the CMO of Alkahest. Raffaele Baffa → Raffaele Baffa has signed on to be CMO at CARsgen, which is attempting to wedge its way into the BCMA CAR-T space with CT053 for multiple myeloma. Baffa pivots to CARSgen from Ziopharm Oncology ( now known as Alaunos after the activist attack dust has settled), where he was CMO and EVP of R&D. The Sanofi and Pfizer vet has also been CMO of Servier and VP, therapeutic area head of oncology, global clinical development at Shire. → Jan Pinkas has been elevated to CSO of Pyxis Oncology as Ronald Herbst parts ways with the Pfizer ADC spinout. Last August, Pinkas joined Pyxis — which hit Nasdaq the following October on the strength of a $168 million IPO — as SVP, preclinical R&D after a two-year stint at Magenta Therapeutics as SVP, translational sciences. He also had a number of responsibilities over a 12-year period at ImmunoGen, namely VP, translational R&D. Ravi Rao → Eli Lilly immunometabolism partner Sitryx Therapeutics out of Oxford has selected Ravi Rao as CMO. Rao — a former GlaxoSmithKline exec in immunology and specialty medicines who was also a group medical director, immunology clinical development with Roche — was head of R&D and CMO at Sobi before choosing a different path here at GSK-backed Sitryx. Anders Ullman has since taken over Rao’s old posts at Sobi. Mikael Eliasson → Helmed by Stanford’s Amit Etkin, psychiatry startup Alto Neuroscience has looked toward Genentech/Roche to appoint Mikael Eliasson as COO. Eliasson, who was previously Genentech/Roche’s global head of innovation in neuroscience product development, has also been global head of new products at Novartis. Christian Angermayer and the folks at Apeiron Investment Group led Alto Neuroscience’s Series A round last October, bringing the total raised to $40 million. → Jotin Marango has left Aptose to tackle the dual roles of CFO and head of corporate development with Ikena Oncology, which is partnering with Bristol Myers on its oral AHR inhibitor IK-175. Marango had been CFO and CBO at Aptose, prompting a leadership shuffle in which CEO William Rice is picking up the slack as chief accounting officer and VP of finance Janet Clennett “will assume financial responsibilities until a permanent CFO is announced.” Karen Davies → Co-founded by Feng Zhang and padding its war chest with an $80 million Series B last month, CRISPR diagnostic player Sherlock Biosciences has trained a magnifying glass on Karen Davies as chief development officer. For the past decade, Davies has held a series of posts at fellow diagnostic developer Quidel — from 2017-20 she was VP of instrument systems, and since 2020 she served as VP of business transformation. Amanda Murphy → Amanda Murphy has resigned from her role as CFO at cell engineering player MaxCyte, effective April 15. Ron Holtz, the current SVP and chief accounting officer, will take over as interim CFO. While Korn Ferry helps in the search for a successor, Holtz is returning to the role he first held at MaxCyte from 2005-20. Elsewhere, MaxCyte staffer Sean Menarguez has been bumped up to director, investor relations. Shabir Hasham → Seeking to put a bow on an NDA filing for its Duchenne muscular dystrophy drug vamorolone by June, Santhera has promoted Shabir Hasham to CMO. Hasham left Novartis in 2015 to become Santhera’s head of medical affairs EU & RoW, and since 2019 he’s been global development program lead & global head medical affairs. While with Novartis, Hasham was EU medical director and global associate brand director for the Swiss pharma’s neuroscience franchise. Hasham’s first day as medical chief is slated for May 1. Cristina Oliva → Cristina Oliva is making her way over to Norway-based BerGenBio, where she’ll serve as CMO. Oliva hops aboard after a stint as VP, oncology and head of oncology centre of excellence at IQVIA. Oliva’s résumé includes a star-studded career with previous roles at Nordic Nanovector, Takeda, GSK and Eli Lilly. → Undergoing a facelift by officially renaming itself a couple weeks ago, Swedish cancer outfit Vivesto — once known as Oasmia — has pegged Daniel Tesfa as CMO. Tesfa had been medical director, clinical and translation science hematology at Sobi since leading oncology and hematology for Bayer in Scandinavia from 2018-20. Vivesto will utilize Lonza’s expanded site in Nansha, China, striking a deal in late March with the CDMO to manufacture late-stage ovarian cancer candidate Cantrixil. → Alliance Pharma is locking in Patrick Bennett to helm the bioanalytical services company as CEO, succeeding founder Frank Li, who will remain as president and on the board of directors. Bennett brings with him experience from his time at PPD Laboratories (VP, strategy and development) and Thermo Fisher Scientific (director of global strategic marketing). Richard Bartram → Peptide specialist MBX Biosciences is picking up former Esperion exec Richard Bartram as CFO. Bartram served in the same role during his time at Esperion — helping to raise more than $1.2 billion in capital. Prior to that stint, Bartram was with PricewaterhouseCoopers. → Vaxxas, the company that Merck teamed up with back in 2020 to tap into patch delivery tech, has named Dan Devine as CBO and general counsel. Devine joins the Brisbane, Australia-based company with experience from his roles at Pfizer, Patrys and Mesoblast. James Gruber → James Gruber has been named CFO at Alkindi Sprinkle maker Eton Pharmaceuticals, taking over the position from Wilson Troutman, who will retire at the end of May. Gruber most recently served as US controller at Horizon Therapeutics and he also spent more than a decade working in various financial positions at Abbott. Libbie Mansell → As the calendar flipped to 2022, Javier Szwarcberg was named CEO of Spruce Biosciences, and now the Mike Grey-chaired biotech focused on rare endocrine disorders has brought in Libbie Mansell as chief regulatory and quality officer. If it seems like it wasn’t that long ago since Mansell appeared in Peer Review, you’re right: Six months ago she joined NFLection Therapeutics as SVP of global regulatory affairs & quality assurance, but it’s on to the next challenge. Mansell was also part of the AskBio team as SVP of regulatory affairs. → Nautilus Biotechnology — backed by Paul Allen and Jeff Bezos and setting sail for Nasdaq via one of Perceptive’s blank-check companies last year — has signed on Gwen Weld as chief people officer and Sheri Wilcox as VP of affinity reagent development. Prior to joining Nautilus, Weld was chief people officer at Amperity and formerly general manager of human resources at Microsoft. Meanwhile, Wilcox hails from SomaLogic. where she served as senior director of global scientific engagement. Before that, she was with Pharmacia. → Karina Fedasz, who began her career at JP Morgan and was recently the CFO of IDW Media Holdings, has been named head of business development at Evofem, the maker of contraceptive gel Phexxi. In February, Endpoints News’ Beth Snyder Bulik spoke with Evofem CEO Saundra Pelletier about a number of topics, namely Phexxi’s ad campaign featuring “Schitt’s Creek” star Annie Murphy. Heather Vital → Jo Viney’s Seismic Therapeutic, using machine learning to develop immunology drugs and launching with a tectonic plate-shifting $101 million Series A in February, has added two execs: Eric Larson (SVP of finance) reunites with Viney, the CEO of Pandion before it was sold to Merck for $1.85 billion last year. Before Larson was Viney’s VP of finance, he served as corporate controller for Proteostasis Therapeutics. After nearly seven years with Biogen, Heather Vital (VP of R&D strategy) jumped to Deciphera Pharmaceuticals as senior director of program leadership and then moved on to her most recent gig as senior director, portfolio strategy and operations for Relay Therapeutics. → TCR biotech TScan Therapeutics has a new VP, finance in Leiden Dworak, who was previously VP, head of financial planning and analysis and business operations at Avrobio. Dworak has also served as the finance lead for global vaccines business development at Moderna. Lyndah Dreiling → California-based Korlym maker Corcept Therapeutics has three new execs ready to roll: First, Daniel Einhorn (VP, endocrine strategy) was the president of Diabetes and Endocrine Associates and medical director of Scripps Whittier Diabetes Institute in San Diego. Amiel Balagtas (VP, development operations) joins the list of Gilead vets at Corcept that includes chief HR and communications officer Amy Flood and chief development officer William Guyer, capping off a 23-year career at the Big Pharma as executive director, development systems. And Lyndah Dreiling (VP, global oncology development), who also has Gilead ties as senior director, clinical research oncology, is an Amgen alum who was recently SVP, clinical development with Spectrum Pharmaceuticals. → New Jersey-based Cellectar Biosciences has two announcements this week: Matthew Hagan has been appointed VP, marketing and strategic alliances, and David Lasecki has joined the oncology biotech as executive director, strategic alliances. Most recently, Hagan served as executive director, hematology portfolio marketing at Bristol Myers. Lasecki joins from Heron Therapeutics, where he served as senior director, oncology sales. Michael Morrissey → Exelixis president and CEO Michael Morrissey has been named chairman of the board at Vera Therapeutics, stepping into the spot previously occupied by Abingworth’s Kurt von Emster. The atacicept developer’s board also includes Beth Seidenberg from Westlake Village BioPartners and Akero Therapeutics CEO Andrew Cheng. → There’s a changing of the guard on the board of directors at Cytokinetics, as John Henderson replaces the retiring Robert Gage. Henderson, a 25-year Pfizer vet, has been on the board at Cytokinetics since 2009. Cardiologist and Stanford Department of Medicine chairman Robert Harrington has also earned a seat on Cytokinetics’ board. Maria Fardis → CRISPR Therapeutics has put Maria Fardis’ name forward to join the board of directors. When her time was up as CEO of Iovance, Fardis then became a venture partner at Frazier Life Sciences. If elected, Fardis would take a seat at a board that includes SR One’s Simeon George and AskBio’s Kathy High. → Michel Detheux, the president and CEO of iTeos Therapeutics, has assumed the role of chairman of the board at French rare bone disease biotech InnoSkel. Detheux co-founded iTeos 10 years ago and is also chairman of ONA Therapeutics in Barcelona. → Lipocine has brought on Jill Jene and Spyros Papapetropoulos to its board of directors. Jene is currently founder and principal of Jene Advisors and has previously served as VP and head of corporate development, strategy, portfolio planning and alliance management at Adamas. Meanwhile, Papapetropoulos is the CMO of Vigil Neurosciences and was formerly SVP, head of development at Acadia Pharmaceuticals, CEO of SwanBio Therapeutics and head of research & development and CMO at Cavion. AUTHORS Amber Tong Senior Editor As a drug formerly abandoned by Gilead finally looks set to complete its tortuous journey toward FDA approval, GlaxoSmithKline is shelling out $1.9 billion to snap it up. Sierra Oncology gets the credit for salvaging momelotinib — which Gilead first obtained through acquiring YM BioSciences for $510 million, but offloaded in 2018 following late-stage failure — and steering it to a positive Phase III readout earlier this year. Started by the crew that used to run YM, Sierra had paid only $3 million in cash to scoop up the drug, in addition to $192 million in biobucks that Gilead will likely pocket given its success. Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor When Be Biopharma revealed itself a year and a half ago with $52 million, the Longwood-founded startup was confident about its vision of creating a new class of medicines out of B cells — but not quite sure yet where it would start. The company, which licensed its B cell engineering platform from Seattle Children’s Hospital, had only two employees. Now, with 64 on staff — led by CEO Joanne Smith-Farrell and CSO Rick Morgan, both bluebird vets — Be Bio is finally ready to declare the initial areas of focus. And ARCH Venture Partners is hopping in to lead a $130 million round to lay the long path toward the clinic. Read More Zachary Brennan Senior Editor A group of 30 bipartisan lawmakers sent letters to 7 naloxone manufacturers, calling on them to apply for over-the-counter status for their opioid overdose antidotes and open up supplies further as the opioid crisis continues in the US with record levels of overdoses and deaths. Citing a Massachusetts study that found substantially increased access to naloxone reduced opioid overdose mortality rates by 46%, the senators and representatives called on Pfizer, Teva Pharmaceuticals, Adamis Pharmaceuticals, Akorn, Amphastar Pharmaceuticals, Emergent BioSolutions, and Hikma Pharmaceuticals to “submit applications to make naloxone available over the counter without delay.” Read More Beth Snyder Bulik Senior Editor A handful of prominent oncology pharmas are teaming up on a next-gen diagnostics initiative, with the ambitious vision of testing for all cancer patients. Bayer, GlaxoSmithKline, Novartis and Roche are leading the Precision Cancer Consortium’s drive to open up biomarker testing on a global scale. The new group will try to boost biomarker testing in two ways — by increasing awareness about the value of genomic testing and by working to improve genomic biomarker testing in clinical trials, it said in a press release . Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Merck hasn’t sold Zostavax in the US since 2020, but that’s not stopping the lawsuits. Thousands of cases charging Zostavax side effects, efficacy issues and advertising and marketing complaints are still working their way through courts across the country. Estimates of more than 2,000 cases stand, although Merck has been picking up some wins lately. Its most recent dismissal on Tuesday absolved the drugmaker in a class action case in Ohio charging that Merck’s “aggressive marketing campaign” for Zostavax contained false claims around effectiveness and protection duration. It alleged, for instance, that Merck promoted a 51% effectiveness rate, when it was actually lower for older age groups. The lawsuits claimed Merck violated Ohio consumer sales practice laws. Read More Zachary Brennan Senior Editor Almost a week after finalizing its restrictive decision for amyloid-targeted Alzheimer’s drugs, the Centers for Medicare and Medicaid Services (CMS) now appears to be walking back the idea that this decision will have a ripple effect across other accelerated approvals. The comments, made at a Duke-Margolis event Tuesday and covered by multiple media outlets, come as biopharma industry groups have warned in recent days that this CMS coverage decision could create a “dangerous precedent” for drugs approved under the accelerated pathway — even as CMS has always had the ability to apply its so-called Coverage with Evidence Determination, but never has actually required an additional randomized controlled trial. Read More April 13, 2022 10:43 AM EDT Kyle LaHucik Associate Editor AbbVie president and vice chair Michael Severino is leaving the Chicago-area pharma giant on May 31 to become a CEO-partner at prolific biotech creator Flagship Pioneering in June. He’s the third CEO-partner to be named at the incubator, which is behind the likes of Moderna, in the past six days. He notified the Humira drugmaker on April 8 of his new career ambitions, according to an AbbVie SEC filing Wednesday morning. He’s departing after three and a half years in the president and vice chair posts. Prior to that, he spent nearly five years as CSO. Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN
Amperity Web Traffic
Amperity Rank
You May Also Like

mParticle puts app owners in full control of their data assets while helping to solve many of the complications that go along with running a mobile business. mParticle not only solves the core challenges of truly creating personalization in mobile but also gives app owners better marketing insights, autonomy from IT cycles, accelerates the launch of new partners/campaigns, and significantly improves app performance & stability. Through a unique approach to mobile data management, mParticle empowers clients to collect, organize and synchronize data, from mobile web and apps.

ActionIQ is an enterprise customer data platform that aims to solve the problems marketers face including the flow and scale of data, analytics, and campaigns.

Tealium enables global businesses to unlock their customer data and create meaningful, relevant customer experiences. The company's customer data platform, comprised of an enterprise tag management solution, omnichannel customer segmentation and action engine, and suite of rich data services, creates a vendor-neutral data foundation that spans web, mobile, offline and IoT.

BlueConic helps brands optimize cross-channel marketing opportunities through improved customer engagement. It offers a SaaS-based online customer engagement platform that leverages a Big Data profile interaction store and machine learning to help marketers synchronize relevant communications across web, mobile and social channels in real time.

Lytics provides adaptive digital marketing and offers a marketing activation platform that integrates all touch points and surfaces behaviors of customers and prospects to recommend how to best target audiences across Web, mobile, email, and social channels. Through machine learning, its cloud-based software predicts SmartAudience segments and suggests opportunities to marketers to adapt their tactics in real-time.

Zeotap is a customer intelligence platform that helps companies better understand their customers and predict behaviors, to invest in more meaningful experiences.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.